Page last updated: 2024-12-11

1,25-dihydroxy-19-norvitamin d3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,25-Dihydroxy-19-norvitamin D3: A Synthetic Vitamin D Analogue

1,25-Dihydroxy-19-norvitamin D3 (also known as **calcipotriol**) is a **synthetic vitamin D analogue**. It's a powerful drug with several important properties, making it a subject of extensive research.

**Here's a breakdown of its characteristics and importance in research:**

* **Structure:** 1,25-Dihydroxy-19-norvitamin D3 is structurally similar to the natural hormone **1,25-dihydroxyvitamin D3 (calcitriol)**, which is the active form of vitamin D in the body. However, it differs in the absence of a carbon atom at position 19 in its molecular structure.
* **Mechanism of Action:** Like calcitriol, it binds to the **vitamin D receptor (VDR)**, which is a nuclear receptor present in various cells throughout the body. This binding triggers the activation of specific genes and pathways, leading to a variety of biological effects.
* **Pharmacological Properties:**
* **Potent anti-proliferative activity:** It inhibits cell growth and proliferation, particularly in cells involved in **psoriasis** and other skin disorders.
* **Immunomodulatory effects:** It can modulate the immune system, suppressing inflammation and promoting immune tolerance.
* **Anti-inflammatory effects:** It reduces inflammation by inhibiting the production of pro-inflammatory cytokines.
* **Therapeutic Applications:**
* **Psoriasis treatment:** It's a widely used topical treatment for psoriasis, effectively reducing skin scaling, redness, and inflammation.
* **Other dermatological conditions:** It is also being investigated for the treatment of other skin diseases like acne, vitiligo, and alopecia areata.
* **Cancer research:** Its anti-proliferative properties make it a potential therapeutic agent for various cancers.
* **Immunomodulation:** Its immunomodulatory effects are being explored in autoimmune diseases like multiple sclerosis and rheumatoid arthritis.

**Why is it important for research?**

1. **Improved efficacy and safety:** Researchers continue to investigate the optimal use of 1,25-dihydroxy-19-norvitamin D3, seeking to improve its efficacy, minimize side effects, and develop novel formulations for better delivery and targeted action.
2. **New therapeutic applications:** The unique properties of this synthetic analogue offer exciting opportunities for its use in treating a wider range of diseases beyond psoriasis.
3. **Understanding vitamin D signaling:** Studies with this analogue help researchers unravel the intricate mechanisms of vitamin D signaling and its diverse effects on the body.
4. **Drug development:** 1,25-dihydroxy-19-norvitamin D3 serves as a lead compound for developing newer, more potent and targeted vitamin D analogues with improved pharmacological profiles.

**In conclusion**, 1,25-dihydroxy-19-norvitamin D3 is a powerful synthetic analogue with significant therapeutic potential, making it an active area of research in dermatology, immunology, and oncology. Its investigation holds promise for developing novel treatments and gaining a deeper understanding of vitamin D's role in human health.

1,25-dihydroxy-19-norvitamin D3: RN refers to (1alpha,3beta,7E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9547326
CHEMBL ID119386
SCHEMBL ID12047912
MeSH IDM0222385

Synonyms (19)

Synonym
1alpha,25-dihydroxy-19-norvitamin d3 / 1alpha,25-dihydroxy-19-norcholecalciferol
(7e)-(1r,3r)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
LMST03020074 ,
CHEMBL119386
1,25-dihydroxy-19-norvitamin d3
130447-37-9
20-epi-19-nor-1,25-(oh)2 d3
1alpha,25-(oh)2-19-nor-vitamin d3
1,3-cis-25-dihydroxy-19-norvitamin d3
19-nor-22(e)
19-nor-9,10-secocholesta-5,7-diene-1,3,25-triol, (1alpha,3beta,7e)-
k5zm856psa ,
unii-k5zm856psa
SCHEMBL12047912
19-nor-vitamin d
1,3-cyclohexanediol, 5-((2e)-2-((1r,3as,7ar)-octahydro-1-((1r)-5-hydroxy-1,5-dimethylhexyl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-, (1r,3s)-
19-nor-1.alpha.,25-dihydroxyvitamin d3
PKFBWEUIKKCWEW-WEZTXPJVSA-N
(1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Young chicks were used to evaluate the efficacy of 2 new vitamin D3 analogs relative to 1 alpha-hydroxycholecalciferol (1 alpha-OH D3) for their ability to improve the bioavailability of phytate-bound phosphorus (P) when added to P-deficient maize-soyabean meal diets that were superadequate in cholecalciferol."( Activity of various hydroxylated vitamin D3 analogs for improving phosphorus utilisation in chicks receiving diets adequate in vitamin D3.
Baker, DH; Biehl, RR; Deluca, HF, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID81829In vitro induction of cell differentiation in HL-60 cells relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID216845Binding affinity for human vitamin D binding protein (hDBP) relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID217011Binding affinity for porcine intestinal Vitamin D3 receptor (VDR) relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID110582Hypercalcemic effect by daily sc injection of compound was measured as serum calcium concentration in vitamin D-replete normal NMRI mice relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (22.22)18.2507
2000's15 (55.56)29.6817
2010's6 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.02 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]